Related references
Note: Only part of the references are listed.Plasminogen Activator Inhibitor-1 (PAI-1): A Key Factor Linking Fibrinolysis and Age-Related Subclinical and Clinical Conditions
Matteo Cesari et al.
CARDIOVASCULAR THERAPEUTICS (2010)
Assessment of Cardiovascular Risk and Prevention of Cardiovascular Disease in Women with the Polycystic Ovary Syndrome: A Consensus Statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society
Robert A. Wild et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels
Athanasia Piouka et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2009)
Multiple biomarkers for the prediction of first major cardiovascular events and death
Thomas J. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes - The Framingham Offspring study
JB Meigs et al.
DIABETES (2006)
Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome
F Carmassi et al.
THROMBOSIS RESEARCH (2005)
Tissue plasminogen activator antigen and coronary heart disease
GDO Lowe et al.
EUROPEAN HEART JOURNAL (2004)
The plasminogen activator system in young and lean women with polycystic ovary syndrome
I Tarkun et al.
ENDOCRINE JOURNAL (2004)
Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes - The insulin resistance atherosclerosis study
A Festa et al.
DIABETES (2002)
Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans
A Katz et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2000)
Share Paper
